Journal article
Antifungal prophylaxis in lung transplantation-a world-wide survey
CF Neoh, GI Snell, T Kotsimbos, B Levvey, CO Morrissey, MA Slavin, K Stewart, DCM Kong
American Journal of Transplantation | WILEY | Published : 2011
Abstract
While variations in antifungal prophylaxis have been previously reported in lung transplant (LTx) recipients, recent clinical practice is unknown. Our aim was to determine current antifungal prophylactic practice in LTx centers world-wide. One nominated LTx clinician from each active center was invited by e-mail to participate in a web-based survey between September 2009 and January 2010. Fifty-seven percent (58/102) responded. The majority of responses were from medical directors of LTx centers (72.4%), and from the United States (44.8%). Within the first 6 months post-LTx, most centers (58.6%) employed universal prophylaxis, with 97.1% targeting Aspergillus species. Voriconazole alone, and..
View full abstractGrants
Funding Acknowledgements
We thank Susan Chernenko for her assistance in compiling the contact details of the LTx clinicians. This study was partly funded by an educational grant from Gilead-Australia and New Zealand. The company was not involved in the study design, data analysis or manuscript preparation. A PhD scholarship to C.F.N. by University of Technology MARA is gratefully acknowledged.The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. C.O.M. has been a consultant to, received investigator-initiated grant support from and given lectures for Gilead Sciences, Pfizer, Merck, Schering-Plough and Orphan Australia. M. A. S. has sat on advisory boards for and received research funding from Pfizer, Merck, Schering-Plough and Gilead Sciences.